Platelet-activating factor and metastasis: Calcium-independent phospholipase a2β deficiency protects against breast cancer metastasis to the lung

American Journal of Physiology - Cell Physiology

Volumn 300, Issue 4, 2011, Pages

  Mchowat, Jane ^a   Gullickson, Gail ^a   Hoover, Richard G ^a   Sharma, Janhavi ^a   Turk, John ^b   Kornbluth, Jacki ^a,c  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bromoenol lactone; Endothelium; Inflammation

Indexed keywords

CALCIUM INDEPENDENT PHOSPHOLIPASE A2; CALCIUM INDEPENDENT PHOSPHOLIPASE A2 BETA; THROMBIN; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL ADHESION; CELL COUNT; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME DEFICIENCY; FEMALE; KNOCKOUT MOUSE; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; TUMOR VOLUME; WILD TYPE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GROUP IV PHOSPHOLIPASES A2; HUMANS; LUNG; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PLATELET ACTIVATING FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; MUS;

EID: 79955137383     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00502.2010     Document Type: Article

References (63)

1. Balsinde J, Dennis EA. Bromoenol lactone inhibits magnesium-dependent phosphatidate phosphohydrolase and blocks triacylglycerol biosynthesis in mouse P388D1 macrophages. J Biol Chem 271: 31937-31941 1996.
2. Bao S, Bohrer A, Ramanadham S, Jin W, Zhang S, Turk J. Effects of stable suppression of Group VIA phospholipase A2 expression on phospholipid content and composition, insulin secretion, and proliferation of INS-1 insulinoma cells. J Biol Chem 281: 187-198, 2006.
3. Bao S, Jacobson D, Wohltmann M, Bohrer A, Jin W, Philipson LH, Turk J. Glucose homeostasis, insulin secretion, and islet phospholipids in mice that overexpress iPLA2β in pancreatic β-cells and in iPLA2β-null mice. Am J Physiol Endocrinol Metab 294: E217-E229, 2008.
4. Bao S, Li Y, Lei X, Wohltmann M, Bohrer A, Jin W, Ramanadham S, Tabas I, Turk J. Attenuated free cholesterol loading-induced apoptosis and preserved phospholipid composition of peritoneal macrophages from mice that do not express Group VIA Phospholipase A2. J Biol Chem 282: 27100-27114, 2007.
5. Bao S, Miller DJ, Ma Z, Wohltmann M, Eng G, Ramanadham S, Moley K, Turk J. Male mice that do not express Group VIA Phospholipase A2 produce spermatozoa with impaired motility and have greatly reduced fertility. J Biol Chem 279: 38194-38200, 2004.
6. Bao S, Song H, Wohltmann M, Ramanadham S, Jin W, Bohrer A, Turk J. Insulin secretory responses and phospholipid composition of pancreatic islets from mice that do not express Group VIA phospholipase A2 and effects of metabolic stress on glucose homeostasis. J Biol Chem 281: 20958-20973, 2006.
7. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917, 1959.
8. Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 50: 237-242, 2009.
9. Bussolati B, Biancone L, Cassoni P, Russo S, Rola-Pleszczynski M, Montrucchio G, Camussi G. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol 157: 1713-1725, 2000.
10. Bussolino F, Arese M, Montrucchio G, Barra L, Primo L, Benelli R, Sanavio F, Aglietta M, Ghigo D, Rola-Pleszczynski, MR. Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis. J Clin Invest 96: 940 -952, 1995.
11. Caiazza F, Harvey BJ, Thomas W. Cytosolic phospholipase A2 activation correlates with HER2 overexpression and mediates estrogendependent breast cancer cell growth. Mol Endocrinol 24: 953-968, 2010.
12. Camussi G, Montrucchio G, Lupia E, Arese M, Bussolino F. Platelet-activating factor and angiogenesis. Adv Exp Med Biol 416: 231-234, 1996.
13. Camussi G, Montrucchio G, Lupia E, Soldi R, Comoglio PM, Bussolino F. Angiogenesis induced in vivo by hepatocyte growth factor is mediated by platelet-activating factor synthesis from macrophages. J Immunol 158: 1302-1309, 1997.
14. Cedars A, Jenkins CM, Mancuso DJ, Gross RW. Calcium-independent phospholipases in the heart: mediators of cellular signaling, bioenergetics, and ischemia-induced electrophysiologic dysfunction. J Cardiovasc Pharmacol 53: 277-289, 2009.
15. Cellai C, Laurenzana A, Vannucchi AM, Caporale R, Paglierani M, Di Lollo S, Pancrazzi A, Paoletti F. Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086. Br J Cancer 94: 1637-1642, 2006.
16. Dittmar T, Heyder C, Gloria-Maercker E, Hatzmann W, Zänker KS. Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner. Clin Exp Metastasis 25: 11-32, 2008.
17. Dunham LJ, Stewart HL. A survey of transplantable and transmissible animal tumors. J Natl Cancer Inst 13: 1299-1377, 1953.
18. Ewens A, Mihich E, Ehrke MJ. Distant metastasis from subcutaneously grown E0771 medullary breast adenocarcinoma. Anticancer Res 25: 3905-3915, 2005.
19. Falandry C, Canney PA, Freyer G, Dirix LY. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann Oncol 20: 615-620, 2009.
20. Franchi L, Chen G, Marina-Garcia N, Abe A, Qu Y, Bao S, Shayman JA, Turk J, Dubyak GR, Nunez G. Calcium-independent phospholipase A2 is dispensable in inflammasome activation and its inhibition by bromoenol lactone. J Innate Immun 1: 607-617, 2009.
21. Harris RE. Cyclooxygenase-2 (COX-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17: 55-67, 2009.
22. Hazen SL, Zupan LA, Weiss RH, Getman DP, Gross RW. Suicide inhibition of canine myocardial cytosolic calcium-independent phospholipase A2. Mechanism-based discrimination between calcium-dependent and -independent phospholipases A2. J Biol Chem 266: 7227-7232, 1991.
23. Heyder C, Gloria-Maercker E, Hatzmann W, Niggemann B, Zänker KS, Dittmar T. Role of the beta1-integrin subunit in the adhesion, extravasation and migration of T24 human bladder carcinoma cells. Clin Exp Metastasis 22: 99-106, 2005.
24. Horn SL, Fentiman IS. The role of non-steroidal anti-inflammatory drugs in the chemoprevention of breast cancer. Pharmaceuticals 3: 1550-1560, 2010.
25. Hyde CA, Missailidis S. Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. Int Immunopharmacol 9: 701-715, 2009.
26. Im SY, Ko HM, Kim JW, Lee HK, Ha TY, Lee HB, Oh SJ, Bai S, Chung KC, Lee YB, Kang HS, Chun SB. Augmentation of tumor metastasis by platelet-activating factor. Cancer Res 56: 2662-2665, 1996.
27. Jenkins CM, Han X, Mancuso DJ, Gross RW. Identification of calciumindependent phospholipase A2 (iPLA2)β, and not iPLA2β, as the mediator of arginine vasopressin-induced arachidonic acid release in A-10 smooth muscle cells. Enantioselective mechanism-based discrimination of mammalian iPLA2s. J Biol Chem 277: 32807-32814, 2002.
28. Kell PJ, Creer MH, Crown KN, Wirsig K, McHowat J. Inhibition of platelet-activating factor (PAF) acetylhydrolase by methyl arachidonyl fluorophosphonate potentiates PAF synthesis in thrombin-stimulated human coronary artery endothelial cells. J Pharmacol Exp Ther 307: 1163-1170, 2003.
29. Krishnamoorthy S, Honn KV. Eicosanoids in tumor progression and metastasis. Subcell Biochem 49: 145-168, 2008.
30. Li H, Zhao Z, Wei G, Yan L, Wang D, Zhang H, Turk J, Xu Y. Both host and tumor cell group VIA phospholipase A2 are involved in ovarian cancer development. FASEB J 24: 4103-4116, 2010.
31. Mancuso DJ, Jenkins CM, Gross RW. The genomic organization, complete mRNA sequence, cloning, and expression of a novel human intracellular membrane-associated calcium-independent phospholipase A2. J Biol Chem 275: 9937-9945, 2000.
32. McHowat J, Creer MH. Myocardial phospholipase A2 (PLA2) exhibits unique catalytic features optimized for regulation of cardiovascular function. In: Recent Research Developments in Lipids, edited by Pandalai SG. Trivandrum, India: Research Signpost, 2002, vol. 2, pp. 19-30.
33. McHowat J, Creer MH. Catalytic features, regulation and function of myocardial phospholipase A2. Curr Med Chem Cardiovasc Hematol Agents 2: 209-218, 2004.
34. McHowat J, Kell PJ, O'Neill HB, Creer MH. Endothelial cell PAF synthesis following thrombin stimulation utilizes Ca2-independent phospholipase A2. Biochemistry 40: 14921-14931, 2001.
35. Melnikova V, Bar-Eli, M. Inflammation and melanoma growth and metastasis: the role of platelet-activating factor (PAF) and its receptor. Cancer Metastasis Rev 26: 359-371, 2007.
36. Melnikova VO, Mourad-Zeidan AA, Lev DC, Bar-Eli, M. Plateletactivating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. J Biol Chem 281: 2911-2922, 2006.
37. Melnikova VO, Villares GJ, Bar-Eli M. Emerging roles of PAR-1 and PAFR in melanoma metastasis. Cancer Microenviron 1: 103-111, 2008.
38. Meyer M, McHowat J. The role of platelet-activating factor in the adherence of circulating cells to the endothelium. In: Recent Research Developments in Physiology, edited by Pandalai SG. Trivandrum, India: Research Signpost, 2004, vol. 2, pp. 129-147.
39. Meyer MC, Rastogi P, Beckett CS, McHowat J. Phospholipase A2 inhibitors as potential anti-inflammatory agents. Curr Pharm Des 11: 1301-1312, 2005.
40. Montrucchio G, Lupia E, de Martino A, Battaglia E, Arese M, Tizzani A, Bussolino F, Camussi G. Nitric oxide mediates angiogenesis induced in vivo by platelet-activating factor and tumor necrosis factor-alpha. Am J Pathol 151: 557-563, 1997.
41. Montrucchio G, Lupia E, Battaglia E, Passerini G, Bussolino F, Emanuelli G, Camussi G. Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J Exp Med 180: 377-382, 1994.
42. Moran JM, Buller RML, McHowat J, Turk. J, Wohltmann M, Gross RW, Corbett JA. Genetic and pharmacologic evidence that iPLA2β regulates virus-induced iNOS expression by macrophages. J Biol Chem 280: 28162-28168, 2005.
43. Nicotera TM, Schuster DP, Bourhim M, Chadha K, Klaich G, Corral DA. Regulation of PSA secretion and survival signaling by calciumindependent phopholipase A2beta in prostate cancer cells. Prostate 69: 1270-1280, 2009.
44. Nikolic DM, Gong MC, Turk J, Post SR. SR-A-mediated macrophage adhesion requires coupling of iPLA2 and 12/15-lipoxygenase to RAC activation. J Biol Chem 282: 2065-2073, 2007.
45. Portell C, Rickard A, Vinson S, McHowat J. Prostacyclin production in tryptase and thrombin stimulated human bladder endothelial cells: effect of pretreatment with phospholipase A2 and cyclooxygenase inhibitors. J Urol 176: 1661-1665, 2006.
46. Rastogi P, Beckett CS, McHowat J. Prostaglandin production in human coronary artery endothelial cells is modulated differentially by selective phospholipase A2 inhibitors. Prostaglandins Leukot Essent Fatty Acids 76: 205-212, 2007.
47. Rastogi P, McHowat J. Inhibition of calcium-independent phospholipase A2 prevents inflammatory mediator production in pulmonary microvascular endothelium. Respir Physiol Neurobiol 165: 167-174, 2009.
48. Robert EG, Hunt JD. Lipid messengers as targets for antiangiogenic therapy. Curr Pharm Des 7: 1615-1626, 2001.
49. Sharma J, Turk J, McHowat J. Endothelial cell prostaglandin I2 and platelet-activating factor production are markedly attenuated in the calciumindependent phospholipase A2 knockout mouse. Biochemistry 49: 5473- 5481, 2010.
50. Six DA, Dennis EA. The expanding superfamily of phospholipase A2 enzymes: classification and characterization. Biochim Biophys Acta 1488: 1-19, 2000.
51. Song H, Ramanadham S, Bao S, Hsu FF, Turk J. A bromoenol lactone suicide substrate inactivates group VIA phospholipase A2 by generating a diffusible bromomethyl keto acid that alkylates cysteine thiols. Biochemistry 45: 1061-1073, 2006.
52. Sugiura K, Stock CC. Studies in a tumor spectrum. II. The effect of 2,4,6-triethylenimino-s-triazine on the growth of a variety of mouse and rat tumors. Cancer 5: 979-991, 1952.
53. Sun B, Zhang X, Yonz C, Cummings BS. Inhibition of calciumindependent phospholipase A2 activates p38 MAPK signaling pathways during cytostasis in prostate cancer cells. Biochem Pharmacol 79: 1727-1735, 2010.
54. Sun B, Zhang X, Talathi S, Cummings BS. Inhibition of Ca2β-independent phospholipase A2 decreases prostate cancer cell growth by p53- dependent and independent mechanisms. J Pharmacol Exp Ther 326: 59-68, 2008.
55. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 10: 181-193, 2010.
56. White MC, McHowat J. Protease activation of calcium-independent phospholipase A2 leads to neutrophil recruitment to coronary artery endothelial cells. Thromb Res 120: 597-605, 2007.
57. Wilkins 3rd WP, Barbour SE. Group VI phospholipases A2: homeostatic phospholipases with significant potential as targets for novel therapeutics. Curr Drug Targets 9: 683-697, 2008.
58. Xie Z, Gong MC, Su W, Turk J, Guo Z. Group VIA phospholipase A2 (iPLA2β) participates in angiotensin II-induced transcriptional upregulationof RGS2 in vascular smooth muscle cells. J Biol Chem 282: 25278- 25289, 2007.
59. Xie Z, Su W, Xie D, Turk J, Guo Z. Role of calcium-independent phospholipase A2β in high glucose-induced activation of RhoA, Rho-kinase, and CPI-17 in cultured vascular smooth muscle cells and vascular smooth muscle hypercontractility in diabetic animals. J Biol Chem 285: 8628-8638, 2010.
60. Yamashita S, Ogawa M, Sakamoto K, Abe T, Arakawa H, Yamashita J. Elevation of serum group II phospholipase A2 levels in patients with advanced cancer. Clin Chim Acta 228: 91-99, 1994.
61. Yamashita S, Yamashita J, Ogawa M. Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency. Br J Cancer 69: 1166 -1170, 1994.
62. Yamashita S, Yamashita J, Sakamoto K, Inada K, Nakashima Y, Murata K, Saishoji T, Nomura K, Ogawa M. Increased expression of membrane-associated phospholipase A2 shows malignant potential of human breast cancer cells. Cancer 71: 3058 -3064, 1993.
63. Zhou H, Luo Y, Mizutani M, Mizutani N, Reisfeld RA, Xiang R. T cell-mediated suppression of angiogenesis results in tumor protective immunity. Blood 106: 2026-2032, 2005.